The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors.

By Lauren L C Marotta, V. Almendro, A. Marusyk, M. Shipitsin, Janina Schemme, Sarah R Walker, Noga Bloushtain-Qimron, Jessica J. Kim, Sibgat A. Choudhury, R. Maruyama and 18 more. Journal of Clinical Investigation, 2011

890 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology

View Paper: https://www.semanticscholar.org/paper/91fe7abd6d6204bf8ae6fbac1eaae01e5454361d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. K. Polyak
2. M. Nieto

In Oncology

1. M. Nieto
2. A. Garrido-Castro
3. K. Polyak
4. Yongheng Chen
5. S. Leonov
6. Huajun Zhang
7. Lin Chen
8. Na Liu

Citations in the corpus

• Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment (2019, background): “JAK-mediated activation of STAT transcription factors regulates transcriptional activity of target genes, including cellcycle regulators (63), and the IL6/JAK2/STAT3 pathway plays an important role in the proliferation of CD44+CD24− stem cell–like breast cancer cells, enriched in basal-like tumors (”
• The ins and outs of the epithelial to mesenchymal transition in health and disease. (2011, background): “Along these lines, the JAK2/Stat3 pathway is specifically required for the growth of the CSC population in breast cancer (Marotta et al. 2011).”
• Recent advances in therapeutic strategies for triple-negative breast cancer (2022, background): “In addition, different studies have shown that the Notch [102], Wnt [103], and JAK/STAT [104] pathways are involved in the maintenance of BC CSCs, and the corresponding inhibitors are under clinical investigation.”